Outcome in dogs with curative-intent treatment of localized primary pulmonary histiocytic sarcoma.
chemotherapy
imaging
oncology
pathology
small animal
surgical oncology
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
24
11
2021
received:
24
08
2021
accepted:
26
11
2021
pubmed:
9
12
2021
medline:
18
5
2022
entrez:
8
12
2021
Statut:
ppublish
Résumé
Primary pulmonary histiocytic sarcoma (PHS) is a rare form of dendritic cell or macrophage neoplasia originating within the pulmonary parenchyma. There is limited literature describing prognosis in dogs with PHS receiving curative-intent treatment consisting of surgical excision and adjuvant chemotherapy. The primary objective of this study was to report outcomes in dogs with localized PHS treated with standardized local and systemic therapy. A secondary objective was to identify prognostic factors in this population. A multi-institutional retrospective study was performed and medical records including all surgical and histopathologic reports were retrospectively reviewed. For inclusion, dogs were required to have confirmed localized PHS and they must have undergone curative-intent surgery with resection of all gross primary tumour and enlarged tracheobronchial lymph nodes; additionally, they must have received curative-intent treatment with adjuvant single-agent CCNU chemotherapy. Twenty-seven dogs from six veterinary teaching hospitals and five private practices treated from 2008-2019 were included. The overall median survival time was 432 days. Higher CCNU dose was demonstrated to have a negative impact on survival on univariate, but not multivariable, analysis. Factors that were not found to be associated with survival on univariate analysis included body weight, breed, clinical signs at the time of diagnosis, hypoalbuminaemia, tumour size, lung lobe affected, lymph node metastasis, surgical margins and CCNU dose reductions. This study supports a favourable prognosis for dogs diagnosed with localized PHS treated with curative-intent surgery in addition to adjuvant CCNU chemotherapy and suggests that multimodal treatment may be advisable to attempt to prolong survival.
Substances chimiques
Lomustine
7BRF0Z81KG
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
458-464Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Skorupski KA, Clifford CA, Paoloni MC, et al. CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med. 2007;21(1):121-126.
Moore PF, Affolter VK, Vernau W. Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages. Vet Pathol. 2006;43(5):632-645.
Dervisis NG, Kiupel M, Qin Q, Cesario L. Clinical prognostic factors in canine histiocytic sarcoma. Vet Comp Oncol. 2017;15(4):1171-1180.
Fidel J, Schiller I, Hauser B, et al. Histiocytic sarcomas in flat-coated retrievers: a summary of 37 cases (November 1998-March 2005). Vet Comp Oncol. 2006;4(2):63-74.
Rassnick KM, Moore AS, Russell DS, et al. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma. J Vet Intern Med. 2010;24:1528-1531.
Clifford CA, Skorupski KA, Moore PF. Histiocytic diseases. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier; 2020:791-797.
Skorupski KA, Rodriguez CO, Krick EL, Clifford CA, Ward R, Kent MS. Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy. Vet Comp Oncol. 2009;7(2):139-144.
Klahn SL, Kitchell BE, Dervisis NG. Evaluation and comparison of outcomes in dogs with periarticular and nonperiarticular histiocytic sarcoma. J Am Vet Med Assoc. 2011;239(1):90-96.
Craig LE, Julian ME, Ferracone JD. The diagnosis and prognosis of synovial tumors in dogs: 35 cases. Vet Pathol. 2002;39(1):66-73.
Kagawa Y, Nakano Y, Kobayashi T, Asano K, Takagi S. Localized pulmonary histiocytic sarcomas in Pembroke Welsh Corgi. J Vet Med Sci. 2015;77(12):1659-1661.
Lenz JA, Furrow E, Craig LE, Cannon CM. Histiocytic sarcoma in 14 miniature schnauzers-a new breed predisposition? J Small Anim Pract. 2017;58:461-467.
Purzycka K, Peters LM, Elliott J, et al. Histiocytic sarcoma in miniature schnauzers: 30 cases. J Small Anim Pract. 2020;61:338-345.
Affolter VK, Moore PF. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Vet Pathol. 2002;39:74-83.
Moore PF, Rosin A. Malignant histiocytosis of Bernese mountain dogs. Vet Pathol. 1986;23:1-10.
Wouda RM, Miller ME, Chon E, Stein TJ. Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997-2012). J Am Vet Med Assoc. 2015;246:1230-1237.
Barrett LE, Pollard RE, Zwingenberger A, Zierenberg-Ripoll A, Skorupski KA. Radiographic characterization of primary lung tumors in 74 dogs. Vet Radiol Ultrasound. 2014;55(5):480-487.
Tsai S, Sutherland-Smith JA, Burgess K, Ruthazer R, Sato A. Imaging characteristics of intrathoracic histiocytic sarcoma in dogs. Vet Radiol Ultrasound. 2012;53(1):21-27.
Marlowe KW, Robat CS, Clarke DM, et al. Primary pulmonary histiocytic sarcoma in dogs: a retrospective analysis of 37 cases (2000-2015). Vet Comp Oncol. 2018;16(4):658-663.
LeBlanc AK, Atherton M, Bentley RT, et al. Veterinary cooperative oncology group-common terminology criteria for adverse events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol. 2021;19(2):311-352.
McNiel EA, Ogilvie GK, Powers BE, Hutchison JM, Salman MD, Withrow SJ. Evaluation of prognostic factors for dogs with primary lung tumors: 67 cases (1985-1992). J Am Vet Med Assoc. 1997;211:1422-1427.
Burton JH, Knych HK, Stanley SD, Rebhun RB. Potency and stability of compounded formulations of chlorambucil, melphalan and cyclophosphamide. Vet Comp Oncol. 2017;15:1558-1563.